COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00247416
Recruitment Status : Completed
First Posted : November 1, 2005
Results First Posted : March 7, 2014
Last Update Posted : March 7, 2014
Kentucky Lung Cancer Research Program
Information provided by (Responsible Party):
Susanne Arnold, University of Kentucky

Brief Summary:

The purpose of this study is to find better treatment for lung cancer and to find out what effects the combined treatment of carboplatin and gemcitabine when given with or without dexamethasone have on cancer.

This study will determine if dexamethasone, when given before standard chemotherapy will increase the cancer fighting effects and reduce the side effects of chemotherapy.

Condition or disease Intervention/treatment Phase
Stage IV Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Drug: Gemcitabine Drug: Dexamethasone Drug: Carboplatin Phase 2

Detailed Description:
Subjects enrolled in the study will be placed in one of two treatment arms. All subjects have a 50-50 chance of being placed into either treatment arm. Treatment Arm 1 will receive chemotherapy alone, Treatment Arm 2 will receive chemotherapy with dexamethasone given pre-treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Trail of Carboplatin and Gemcitabine Untreated Stage IIIB-pleural Effusion and Stage IV Lung Cancer
Study Start Date : August 2005
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
1 No Dex
No Dexamethasone
Drug: Gemcitabine
Gemcitabine 1000 mg/m^2 intravenously over 30 minutes on days 5 and 12.
Other Name: Gemzar

Drug: Carboplatin
AUC 6.0 intravenously over 30 minutes on day 5.

Experimental: 2 Dex
Drug: Gemcitabine
Gemcitabine 1000 mg/m^2 intravenously over 30 minutes on days 5 and 12.
Other Name: Gemzar

Drug: Dexamethasone
16 mg bid for 4 days prior to each chemotherapy start.

Drug: Carboplatin
AUC 6.0 intravenously over 30 minutes on day 5.

Primary Outcome Measures :
  1. Percentage of Participants With Reduction in Grade 3/4 Neutropenia [ Time Frame: continuous throughout treatment, up to 25 weeks ]
    Reduction grade 3/4 neutropenia

Secondary Outcome Measures :
  1. Effect of Dexamethasone Pre-treatment on Response Rate. [ Time Frame: Pre-treatment, pre-cycles 3 & 5, and up to 4 weeks after last treatment ]
    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

  2. Effect of Dexamethasone Pre-treatment on Overall Survival. [ Time Frame: Pre-treatment, pre-cycles 3 & 5,4 weeks after last treatment, every 3 months, an average of 471 days ]
    Overall survival

  3. Progression-free Survival [ Time Frame: Pre-treatment, pre-cycles 3 & 5,4 weeks after last treatment, and every 3 months, an average of 471 days ]
    progression-free survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Untreated, stage IIIB with pleural effusion
  • Untreated, Stage IV, non-small cell lung cancer
  • Recurrent after surgery if no previous radiation therapy or chemotherapy were administered as part of their primary treatment, except for palliative radiotherapy
  • 18 years of age or older
  • ECOG PS 0, 1 or 2
  • At Least one target lesion according to the RECIST Criteria
  • Adequate organ and marrow function

Exclusion Criteria:

  • Previous cancer history unless they have had curative treatment completed at least 5 years prior to entry.
  • No previous radiotherapy, chemotherapy or immunotherapy for NSCLC, except for radiation therapy to the brain to control metastasis, bone to control pain, or lung to relieve bronchial obstruction.
  • No radiation therapy for any previous cancer to more than 25% of bone marrow.
  • Uncontrolled, intercurrent illness
  • Non-study corticosteroids
  • Pregnant women
  • Peripheral neuropathy greater than grade 1
  • Uncontrolled seizures, central nervous system disorders
  • Major surgery within 4 weeks of the start of study treatment
  • Lack of complete recovery from major surgery.
  • Glaucoma
  • Lack of physical integrity of upper gastrointestinal tract, inability to swallow tablets
  • Severe acquired or hereditary immunodeficiency
  • Patients with brain metastases must receive definitive treatment (radiation, surgery or both) and be clinically and radiologically stable for 4 weeks & off corticosteroids for at least 2 weeks prior to randomization.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00247416

Layout table for location information
United States, Kentucky
Commonwealth Cancer Center
Danville, Kentucky, United States, 40422
Markey Cancer Center
Lexington, Kentucky, United States, 40536
Brown Cancer Center
Louisville, Kentucky, United States, 40202
St. Claire Regional Medical Center
Morehead, Kentucky, United States, 40351
Montgomery Cancer Center
Mt. Sterling, Kentucky, United States, 40353
Owensboro Medical HealthCare System
Owensboro, Kentucky, United States, 42303
West Kentucky Hematology & Oncology Group, PSC
Paducah, Kentucky, United States, 42003
Sponsors and Collaborators
Susanne Arnold
Kentucky Lung Cancer Research Program
Layout table for investigator information
Principal Investigator: John Rinehart Lucille P. Markey Cancer Center at University of Kentucky

Publications of Results:
Layout table for additonal information
Responsible Party: Susanne Arnold, Sponsor/Investigator, University of Kentucky Identifier: NCT00247416    
Other Study ID Numbers: CTN-0501
First Posted: November 1, 2005    Key Record Dates
Results First Posted: March 7, 2014
Last Update Posted: March 7, 2014
Last Verified: January 2014
Keywords provided by Susanne Arnold, University of Kentucky:
non-small cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Pleural Effusion
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Pleural Diseases
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors